Alpine Immune Sciences Inc (ALPN)

$64.97 +0.01 (0.02%)
Market Cap 4.46B
Revenue (ttm) 58.88M
Net Income (ttm) -32.18M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 4,288,300
Avg Vol 2,714,032
Day's Range N/A - N/A
Shares Out 68.60M
Stochastic %K 93%
Beta 0.97
Analysts Sell
Price Target $60.57
Quantumup
Quantumup Apr. 28 at 2:29 PM
Cantor Fitzgerald reiterated $TVTX at an Overweight rating. $NVS ( $CALT - $AHKSY ( $ALPN - $VRTX)) Cantor Fitzgerald said in its note, "We'd own $TVTX for FSGS approval and a rapid launch driven by: 1) high unmet need (higher than IgAN, per our physician survey), 2) no treatment option, 3) physician familiarity with Filspari and comfort with the safety profile in the real world, 4) no competition for Filspari for several years. Also, Filspari pricing in FSGS (~$280K+ /yr) will likely be double the IgAN price due to the double the dose tested in FSGS. Thus, for blockbuster sales in FSGS, only 4-5K patients need to be on Filspari, or 15-30% of the 15-30K FSGS addressable patients in the U.S."
0 · Reply
Quantumup
Quantumup Feb. 27 at 1:09 PM
Guggenheim⬆️the PT on $VERA to $61 was $59 and reiterated at a Buy rating. $OTSKY $ALPN - $VRTX Guggenheim said in its $VERA PT increase note:
0 · Reply
wyoming2020
wyoming2020 Feb. 1 at 12:34 AM
$PDSB I learned that it's very tough for microcaps to go all in or mostly all in on a single blue chip partner. There are others that were more confident with what they had so went for various partners. We went down the $PRVB path whereas Mitch Gold and $ALPN did it well (smart). There are many others that are doing awesome in that way. Still very happy with the research and end result I think is good but the management should have taken notes on strategy. Iets see what happens! It's been a fun ride on the board. Here till it ends
2 · Reply
wyoming2020
wyoming2020 Jan. 10 at 11:11 PM
$PDSB this absolutely a massive disappointment and no energy from the leadership I like $PRVB or $ALPN. I'll hold bit expecting tax loss. It's a bad market day but we need a business person to assist here and salvage this messy mess.
0 · Reply
NVDAMillionaire
NVDAMillionaire Jan. 8 at 7:10 PM
$ALPN Alpine Immune Sciences, Inc. (NASDAQ:ALPN): Advancing Povetacicept, a Potentially Best-in-Class Dual BAFF/APRIL Inhibitor, Across Multiple Autoimmune Indications https://beyondspx.com/article/alpine-immune-sciences-inc-nasdaq-alpn-advancing-povetacicept-a-potentially-best-in-class-dual-baff-april-inhibitor-across-multiple-autoimmune-indications
0 · Reply
tyrus6
tyrus6 Jan. 4 at 9:32 AM
$CKPT I really went slumming this time. I plugged in "($4.5) Billion into my Google fish in a barrel question and up pops, "Vertex Pharmaceuticals, a Boston-based biotechnology company, acquired Alpine Immune Sciences for approximately $4.9 billion in 2024." News which we all, of course, remember as vividly as the famous debate moment about dog consumption. Right? Nope..NOT at all. I didn't even know that $104 Billion MC Vertex ($VRTX) Pharmaceuticals existed before this, and had never heard of Alpine ($ALPN) or their promising pipeline of "potential," but not yet FDA approved, drugs. Check out the $ALPN buyout chart... And while you do, think about the fact that some would-be buyout sale agents for Checkpoint posted they'd be "happy" to take one billion -- or golly, dream big! $1.5 Billion, ya know, $10 bucks! a $CKPT share -- for a biotech that spent over a decade to get a potentially leading revenue skin cancer drug FDA approved and on the market. Scott Boras they are not.
1 · Reply
biotechdollars
biotechdollars Oct. 19 at 2:04 AM
$ALPN I felt 65 was low for alpn. However I feel great about 65 now. The 303 data was thin. The second set of 303 patients data, released before the acquisition, were not as strong.
0 · Reply
biotechdollars
biotechdollars Oct. 15 at 2:55 AM
$ALPN we own vktx much lower, fortunately. We are picking up bcab. How about you?
1 · Reply
Aigner_Andreas
Aigner_Andreas Aug. 17 at 6:42 AM
TF BUY $ALPN at 6.82 : 6.58 MicroCap -22% Shp 1.3 S 0 N 0 RSI 35.99% SRSI 76.64% ADXR 51.86 #stocks #trading #finance #market
0 · Reply
NVDAMillionaire
NVDAMillionaire Aug. 16 at 6:02 PM
$ALPN Alpine Immune Sciences, Inc. (NASDAQ:ALPN): Advancing Povetacicept, a Potentially Best-in-Class Dual BAFF/APRIL Inhibitor, Across Multiple Autoimmune Indications http://beyondspx.com/2024/08/05/alpine-immune-sciences-inc-nasdaqalpn-advancing-povetacicept-a-potentially-best-in-class-dual-baff-april-inhibitor-across-multiple-autoimmune-indications/
0 · Reply
Latest News on ALPN
No data available.
Quantumup
Quantumup Apr. 28 at 2:29 PM
Cantor Fitzgerald reiterated $TVTX at an Overweight rating. $NVS ( $CALT - $AHKSY ( $ALPN - $VRTX)) Cantor Fitzgerald said in its note, "We'd own $TVTX for FSGS approval and a rapid launch driven by: 1) high unmet need (higher than IgAN, per our physician survey), 2) no treatment option, 3) physician familiarity with Filspari and comfort with the safety profile in the real world, 4) no competition for Filspari for several years. Also, Filspari pricing in FSGS (~$280K+ /yr) will likely be double the IgAN price due to the double the dose tested in FSGS. Thus, for blockbuster sales in FSGS, only 4-5K patients need to be on Filspari, or 15-30% of the 15-30K FSGS addressable patients in the U.S."
0 · Reply
Quantumup
Quantumup Feb. 27 at 1:09 PM
Guggenheim⬆️the PT on $VERA to $61 was $59 and reiterated at a Buy rating. $OTSKY $ALPN - $VRTX Guggenheim said in its $VERA PT increase note:
0 · Reply
wyoming2020
wyoming2020 Feb. 1 at 12:34 AM
$PDSB I learned that it's very tough for microcaps to go all in or mostly all in on a single blue chip partner. There are others that were more confident with what they had so went for various partners. We went down the $PRVB path whereas Mitch Gold and $ALPN did it well (smart). There are many others that are doing awesome in that way. Still very happy with the research and end result I think is good but the management should have taken notes on strategy. Iets see what happens! It's been a fun ride on the board. Here till it ends
2 · Reply
wyoming2020
wyoming2020 Jan. 10 at 11:11 PM
$PDSB this absolutely a massive disappointment and no energy from the leadership I like $PRVB or $ALPN. I'll hold bit expecting tax loss. It's a bad market day but we need a business person to assist here and salvage this messy mess.
0 · Reply
NVDAMillionaire
NVDAMillionaire Jan. 8 at 7:10 PM
$ALPN Alpine Immune Sciences, Inc. (NASDAQ:ALPN): Advancing Povetacicept, a Potentially Best-in-Class Dual BAFF/APRIL Inhibitor, Across Multiple Autoimmune Indications https://beyondspx.com/article/alpine-immune-sciences-inc-nasdaq-alpn-advancing-povetacicept-a-potentially-best-in-class-dual-baff-april-inhibitor-across-multiple-autoimmune-indications
0 · Reply
tyrus6
tyrus6 Jan. 4 at 9:32 AM
$CKPT I really went slumming this time. I plugged in "($4.5) Billion into my Google fish in a barrel question and up pops, "Vertex Pharmaceuticals, a Boston-based biotechnology company, acquired Alpine Immune Sciences for approximately $4.9 billion in 2024." News which we all, of course, remember as vividly as the famous debate moment about dog consumption. Right? Nope..NOT at all. I didn't even know that $104 Billion MC Vertex ($VRTX) Pharmaceuticals existed before this, and had never heard of Alpine ($ALPN) or their promising pipeline of "potential," but not yet FDA approved, drugs. Check out the $ALPN buyout chart... And while you do, think about the fact that some would-be buyout sale agents for Checkpoint posted they'd be "happy" to take one billion -- or golly, dream big! $1.5 Billion, ya know, $10 bucks! a $CKPT share -- for a biotech that spent over a decade to get a potentially leading revenue skin cancer drug FDA approved and on the market. Scott Boras they are not.
1 · Reply
biotechdollars
biotechdollars Oct. 19 at 2:04 AM
$ALPN I felt 65 was low for alpn. However I feel great about 65 now. The 303 data was thin. The second set of 303 patients data, released before the acquisition, were not as strong.
0 · Reply
biotechdollars
biotechdollars Oct. 15 at 2:55 AM
$ALPN we own vktx much lower, fortunately. We are picking up bcab. How about you?
1 · Reply
Aigner_Andreas
Aigner_Andreas Aug. 17 at 6:42 AM
TF BUY $ALPN at 6.82 : 6.58 MicroCap -22% Shp 1.3 S 0 N 0 RSI 35.99% SRSI 76.64% ADXR 51.86 #stocks #trading #finance #market
0 · Reply
NVDAMillionaire
NVDAMillionaire Aug. 16 at 6:02 PM
$ALPN Alpine Immune Sciences, Inc. (NASDAQ:ALPN): Advancing Povetacicept, a Potentially Best-in-Class Dual BAFF/APRIL Inhibitor, Across Multiple Autoimmune Indications http://beyondspx.com/2024/08/05/alpine-immune-sciences-inc-nasdaqalpn-advancing-povetacicept-a-potentially-best-in-class-dual-baff-april-inhibitor-across-multiple-autoimmune-indications/
0 · Reply
biotechdollars
biotechdollars Jul. 1 at 3:12 AM
$ALPN I'd like to communicate off stocktwits, if you have a suggestion. I was not enamored with the 303 Igan second group of 5's performance. First group of 5 stronger.
0 · Reply
tan1642
tan1642 Jun. 19 at 6:30 PM
$IOVA $ALPN $8.54 on 10/26/23. $64.40 on 04/11/24. It can happen.
1 · Reply
Aigner_Andreas
Aigner_Andreas May. 21 at 5:31 AM
TF SELL $ALPN at 6.82 : 64.24 MicroCap 98% Shp 0.62 S 0.09 N 0.2 RSI 7.63% SRSI 0% ADXR 62.23 #stocks #trading #finance #market
0 · Reply
tradethehalt
tradethehalt May. 17 at 11:55 PM
$ALPN trade halt (T12) was alerted to our Members at 7:50pm EDT. Halt price: $64.99 Vol: 4.28M.
0 · Reply
HaltTradeAlert
HaltTradeAlert May. 17 at 11:52 PM
$ALPN Halt Time: 19:50:00 Issue Symbol: ALPN Reason Code: T12 Last Price: $64.97 Market Cap: $4456779918 Volume: 4169642.0 Relative Volume: 2.34 Shares Float: 68597504 Our members get this alert real time and sent to their phone just like a text. Members also get free real time news catalyst alerts! Go to our website and join our community for free! www.HaltTradeAlert.com
0 · Reply
Mergerbrief
Mergerbrief May. 17 at 12:09 PM
$ALPN $VRTX - Tender Offer Expires MergerBrief.com
0 · Reply
CTFNLighthouse
CTFNLighthouse May. 13 at 6:58 PM
$ALPN $VRTX The HSR waiting period in connection with Vertex Pharmaceuticals’ proposed acquisition of Alpine Immune Sciences expired on May 9. The tender offer will expire at one minute past 11:59pm ET on May 17, unless the offer is extended.
0 · Reply
intratio
intratio May. 11 at 2:05 AM
$ALPN https://www.intratio.com/stock-forecast/ALPN The predictive algorithm is predicting the value of this company will soon begin to trend sharply downward and will continue to have a very poor trend over the next months
1 · Reply
epsguid
epsguid May. 9 at 8:04 PM
$ALPN reported a loss of $0.28, consensus was ($0.43) via @eWhispers #epsbeat http://eps.sh/d/alpn
0 · Reply
Stock_Titan
Stock_Titan May. 9 at 8:00 PM
$ALPN $VRTX Alpine Immune Sciences Reports First Quarter 2024 Financial Results https://www.stocktitan.net/news/ALPN/alpine-immune-sciences-reports-first-quarter-2024-financial-vo4a5lekydep.html
0 · Reply
intratio
intratio May. 9 at 2:01 AM
$ALPN https://www.intratio.com/stock-forecast/ALPN Our algorithm has detected that this stock s value has a rather grim outlook for the immediate future and predicts a gravely bleak future
1 · Reply
ScottieJay541
ScottieJay541 May. 8 at 6:11 PM
$ALPN Earnings is going to take this to 70+
0 · Reply